Cetuximab (Erbitux®), an anti-EGFR chimeric IgG1 antibody, was used to metastatic colon cancer and head and neck squamous cell carcinoma (HNSCC). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.